Abstergo Industries, a multinational corporation, reported a successful year in genetic research in 2023, aiming for further developments in 2024. Specializing in the study and application of genetic data, Abstergo has made breakthroughs in areas like disease cure development and genetic traits identification. For 2024, they plan to enhance their genetic memory exploring device, the Animus, and expand their global data network, Eye-Abstergo.
Abstergo Industries is pioneering developments in cancer drug research, focusing on immunotherapy, targeted therapies, genetics of cancer, and prevention strategies. The company’s primary concern is their newly developed cancer drug, Oncolux, a targeted therapy displaying promising results in preclinical trials for its capacity to destroy cancer cells without harming healthy ones. Abstergo aims to revolutionize the field, aspiring to improve patient lives and contribute significantly to future cancer research.
Abstergo Industries is proud to announce our latest satellite program, the Akashic Satellite Plexus® 2.0. This program builds on the success of our previous satellite programs, including the original Akashic Satellite Plexus® launched in 2008 and the EYE-ABSTERGO® satellite launched in 2012. Our goal with this new program is to extend the reach and capabilities […]
Abstergo Industries is dedicated to advancing the science of aging and developing treatments to slow the aging process. Aging is a complex process that involves a variety of biological pathways and mechanisms, including genetic, environmental, and lifestyle factors. Our research focuses on understanding these pathways and developing interventions that can target them to extend healthy […]
Abstergo Industries is excited to announce the development of a new pharmaceutical product that has the potential to revolutionize the treatment of a wide range of conditions. The new drug, which is currently in the early stages of clinical trials, targets a specific enzyme that plays a key role in a variety of physiological processes. […]